Market Spotlight: Dry Eye Disease
Market Spotlight: Dry Eye Disease
$1,318.00
This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2020, there were 1.52 billion prevalent cases of dry eye disease worldwide, and forecasts that number to increase to 1.72 billion prevalent cases by 2029.
- The approved drugs in the dry eye space focus on a wide variety of targets. The majority of approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival and intranasal formulations.
- The majority of industry-sponsored drugs in active clinical development for dry eye are in Phase II. Therapies in development for dry eye focus on a wide variety of targets. The majority of pipeline drugs are administered via the topical route.
- High-impact upcoming events for drugs in the dry eye space comprise topline Phase II trial results for NRO-1, ECF843, OTX-CSI, and IC-265; and topline Phase III trial results for CyclASol, HL036, and PL-9643.
- The overall likelihood of approval of a Phase I dry eye asset is 12.2%, and the average probability a drug advances from Phase III is 33.3%. Drugs, on average, take 8.2 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for dry eye have been in the late phases of development, with 56% of trials in Phase III–IV compared to 44% in Phase I–II.
- The US has a substantial lead in the number of dry eye clinical trials globally. France leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the dry eye space is dominated by completed trials. Novartis has the highest number of completed clinical trials for dry eye, with 88 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for dry eye, followed by AbbVie.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
10 TREATMENT
10 Ocular lubricants
10 Prescription drugs
11 Eyelid hygiene
12 Surgical treatment
13 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 NovaTears for Dry Eye (September 30, 2021)
29 AR-15512 for Dry Eye (September 15, 2021)
31 NovaTears for Dry Eye (April 13, 2021)
33 RGN-259 for Dry Eye (March 18, 2021)
35 Visomitin for Dry Eye (February 22, 2021)
37 Reproxalap for Dry Eye (January 7, 2021)
39 NovaTears for Dry Eye (December 22, 2020)
41 PL-9643 for Dry Eye (December 15, 2020)
42 Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)
44 OC-01 Nasal Spray for Dry Eye (May 11, 2020)
46 KEY UPCOMING EVENTS
47 KEY REGULATORY EVENTS
47 Oyster Point Prepares Major Push For New Dry Eye Drug
47 Bausch Health Lubricates Bausch + Lomb’s Pending Separation With Hydration Eye Drops Launch
47 Japan’s Rohto Offers Brits Dry Eye Relief As Screen Time Soars
48 Oyster Point Pharma Submits NDA For OC-01 Nasal Spray
48 FDA Approves Eysuvis For Dry Eye Disease
49 PROBABILITY OF SUCCESS
50 LICENSING AND ASSET ACQUISITION DEALS
50 Acquisition By HLB Group To Speed Up GtreeBNT’s Programs
50 Stada Partners With NTC For Ophthalmic Brands In MENA
50 Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn’t
52 REVENUE OPPORTUNITY
53 CLINICAL TRIAL LANDSCAPE
54 Sponsors by status
55 Sponsors by phase
56 Recent events
58 BIBLIOGRAPHY
59 APPENDIX
LIST OF FIGURES
16 Figure 1: Trends in prevalent cases of dry eye disease, 2020–29
20 Figure 2: Overview of pipeline drugs for dry eye disease in the US
20 Figure 3: Pipeline drugs for dry eye disease, by company
21 Figure 4: Pipeline drugs for dry eye disease, by drug type
21 Figure 5: Pipeline drugs for dry eye disease, by classification
29 Figure 6: NovaTears for Dry Eye (September 30, 2021): Phase III – MOJAVE
31 Figure 7: AR-15512 for Dry Eye (September 15, 2021): Phase IIb – COMET-1
33 Figure 8: NovaTears for Dry Eye (April 13, 2021): Phase III – GOBI
35 Figure 9: RGN-259 for Dry Eye (March 18, 2021): Phase III – ARISE-3 (US)
37 Figure 10: Visomitin for Dry Eye (February 22, 2021): Phase III – VISTA-2
39 Figure 11: Reproxalap for Dry Eye (January 7, 2021): Phase III – TRANQUILITY
41 Figure 12: NovaTears for Dry Eye (December 22, 2020): Phase II – SEECASE
42 Figure 13: PL-9643 for Dry Eye (December 15, 2020): Phase II – PL9643-201
44 Figure 14: Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020): Phase II/III – AUDREY
45 Figure 15: OC-01 Nasal Spray for Dry Eye (May 11, 2020): Phase III – ONSET-2
46 Figure 16: Key upcoming events in dry eye disease
49 Figure 17: Probability of success in the dry eye pipeline
53 Figure 18: Clinical trials in dry eye disease
53 Figure 19: Top 10 drugs for clinical trials in dry eye disease
54 Figure 20: Top 10 companies for clinical trials in dry eye disease
54 Figure 21: Trial locations in dry eye disease
55 Figure 22: Dry eye disease trials status
56 Figure 23: Dry eye disease trials sponsors, by phase
LIST OF TABLES
14 Table 1: Prevalent cases of dry eye disease, 2020–29
18 Table 2: Marketed drugs for dry eye disease
22 Table 3: Pipeline drugs for dry eye disease in the US
28 Table 4: NovaTears for Dry Eye (September 30, 2021)
30 Table 5: AR-15512 for Dry Eye (September 15, 2021)
32 Table 6: NovaTears for Dry Eye (April 13, 2021)
34 Table 7: RGN-259 for Dry Eye (March 18, 2021)
36 Table 8: Visomitin for Dry Eye (February 22, 2021)
37 Table 9: Reproxalap for Dry Eye (January 7, 2021)
40 Table 10: NovaTears for Dry Eye (December 22, 2020)
41 Table 11: PL-9643 for Dry Eye (December 15, 2020)
43 Table 12: Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)
44 Table 13: OC-01 Nasal Spray for Dry Eye (May 11, 2020)
52 Table 14: Historical global sales, by drug ($m), 2016–20
52 Table 15: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Uterine Fibroids 
Sign up to the